Exchange: NASDAQ·Updated 12:26 PM EDT

IRD News

News
all
press releases
Five Market Stories Heating Up Right Now
The latest market developments are putting investors’ attention back on tangible catalysts: NeOnc Technologies Holdings (NASDAQ:NTHI) is pairing fresh institutional capital with encouraging NEO100 clinical data; Opus Genetics (NASDAQ:IRD) is advancing OPGx-BEST1 toward potential pivotal development after positive early data and FDA feedback; bioAffinity Technologies (NASDAQ:BIAF) removed its Nasdaq compliance overhang while continuing to commercialize CyPath Lung; Tenon Medical (NASDAQ:TNON) eliminated roughly $5.16 million of convertible-note obligations ahead of maturity; Sunation Energy (NASDAQ:SUNE) is positioned at the center of Suniva’s $835 million financing and planned expansion to 5.5 GW of U.S. solar-cell capacity; and The OLB Group (NASDAQ:OLB) is attempting to build a rebound momentum after recently hitting a new 52-week low and, yes, I know that’s a sixth company.
24-7 Market News
More News
Gene Therapy at Lower Dose Shows Vision Improvements, Opus Genetics Says
Opus Genetics posts positive Phase 1/2 trial results for OPGx-BEST1 and aligns with the FDA on Phase 3 plans for 2027.read more...
Benzinga
Caleres Posts Upbeat Q2 Earnings, Joins Opus Genetics, Flotek Industries And Other Big Stocks Moving Higher On Wednesday
U.S. stocks fell, but Caleres surged 14% on strong results and higher guidance. Opus Genetics, Signet and Oddity also posted big gains.read more...
Benzinga
Five High-Voltage Stories in Focus
The market is once again rewarding investors who know where to look for catalysts, bioAffinity Technologies (NASDAQ:BIAF), NeOnc Technologies Holdings (NASDAQ:NTHI), Opus Genetics (NASDAQ:IRD), Eos Energy Enterprises (NASDAQ:EOSE) with Google (NASDAQ:GOOG), and Scorpio Gold (NASDAQ:SGLD) each have a distinctly different catalyst driving their narratives.
24-7 Market News
Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates
Opus Genetics, Inc. (IRD) delivered earnings and revenue surprises of +6.67% and -75.03%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Qiagen (QGEN) Beats Q2 Earnings and Revenue Estimates
Qiagen (QGEN) delivered earnings and revenue surprises of +3.33% and +1.35%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
RBC Capital Bullish On Opus Genetics (IRD) Amid Limited Competition And De-Risked Setup
RBC Capital Bullish On Opus Genetics (IRD) Amid Limited Competition And De-Risked Setup...
Yahoo! Finance: News
Opus Genetics, Inc. (IRD) Reports Q1 Loss, Misses Revenue Estimates
Opus Genetics, Inc. (IRD) delivered earnings and revenue surprises of -374.68% and -23.18%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Certara, Inc. (CERT) Q1 Earnings Miss Estimates
Certara (CERT) delivered earnings and revenue surprises of -20.57% and +1.22%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Opus Genetics, Inc. (NASDAQ:IRD) Receives Average Recommendation of "Moderate Buy" from Analysts
Opus Genetics, Inc. (NASDAQ:IRD - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the thirteen analysts that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating...
MarketBeat

Advertisement|Remove ads.